Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.56 |
| ▸ | NPC1 | O15118 | 3/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | PKM | P14618 | 3/20 | 0.53 |
| ▸ | RAB9A | P51151 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 6/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.50 |
| ▸ | MAPT | P10636 | 4/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | HTT | P42858 | 2/20 | 0.48 |
| ▸ | GFER | P55789 | 1/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.45 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.45 |
| ▸ | RELA | Q04206 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12640326 | 0.80 | NPC1 (0.50) | SMN1; SMN2NPC1ALDH1A1KDM4EMAPK1 | |
| SCHEMBL18286277 | 0.78 | NPC1 (0.53) | NPC1RAB9AVNN1 | |
| SCHEMBL23609081 | 0.78 | ALDH1A1 (0.62) | SMN1; SMN2NPC1ALDH1A1KDM4EMAPK1 | |
| SCHEMBL1266734 | 0.78 | NPC1 (0.62) | SMN1; SMN2NPC1ALDH1A1KDM4EMAPK1 | |
| SCHEMBL12640325 | 0.76 | NPC1 (0.56) | SMN1; SMN2NPC1ALDH1A1KDM4EMAPK1 | |
| SCHEMBL1266913 | 0.74 | NPC1 (0.58) | SMN1; SMN2NPC1ALDH1A1KDM4EMAPK1 | |
| SCHEMBL1083657 | 0.74 | NPC1 (0.62) | SMN1; SMN2NPC1ALDH1A1KDM4EMAPK1 | |
| SCHEMBL12477520 | 0.74 | CXCR4 (0.70) | NPC1ALDH1A1KDM4ERAB9AMEN1 | |
| SCHEMBL29379149 | 0.74 | CXCR4 (0.70) | NPC1ALDH1A1KDM4ERAB9AMEN1 | |
| SCHEMBL28780861 | 0.73 | NPC1 (0.57) | SMN1; SMN2NPC1ALDH1A1KDM4EMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190292157-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS INHIBITORS OF VANIN-1 ENZYME | PFIZER INC. (US) | 2019-09-26 | — | — | US | disclosed |
| US-20190292157-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS INHIBITORS OF VANIN-1 ENZYME | PFIZER INC. (US) | 2019-09-26 | — | — | US | disclosed |
| US-10308615-B2 | Heterocyclic compounds as inhibitors of Vanin-1 enzyme | PFIZER INC. (US) | 2019-06-04 | — | — | US | disclosed |
| US-10308615-B2 | Heterocyclic compounds as inhibitors of Vanin-1 enzyme | PFIZER INC. (US) | 2019-06-04 | — | — | US | disclosed |
| US-20180148420-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS INHIBITORS OF VANIN-1 ENZYME | PFIZER INC. (US) | 2018-05-31 | — | — | US | disclosed |
| US-20180148420-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS INHIBITORS OF VANIN-1 ENZYME | PFIZER INC. (US) | 2018-05-31 | — | — | US | disclosed |
| US-20180148420-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS INHIBITORS OF VANIN-1 ENZYME | PFIZER INC. (US) | 2018-05-31 | — | — | US | disclosed |
| EP-3303303-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS INHIBITORS OF VANIN-1 ENZYME | Pfizer Inc (US) | 2018-04-11 | — | — | EP | disclosed |
| WO-2016193844-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS INHIBITORS OF VANIN-1 ENZYME | PFIZER INC. (US) | 2016-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190292157-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS INHIBITORS OF VANIN-1 ENZYME | VNN1, VAT1, CMA1 | SMN1; SMN2 3862/4885NPC1 1266/4885ALDH1A1 256/4885 |
| US-10308615-B2 | Heterocyclic compounds as inhibitors of Vanin-1 enzyme | VNN1, MVD, VAT1 | SMN1; SMN2 3147/4885NPC1 1440/4885ALDH1A1 228/4885 |
| US-20180148420-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS INHIBITORS OF VANIN-1 ENZYME | VNN1, CMA1, VAT1 | SMN1; SMN2 3720/4885NPC1 1097/4885ALDH1A1 168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.